If you want the shortest useful answer: the Medicare GLP-1 Bridge starts on July 1, 2026, not sooner, and the best way to prepare is to organize your paperwork before your prescriber starts the prior authorization. As of April 15, 2026, CMS says the bridge is a temporary program that runs through December 31, 2026, covers Wegovy and Zepbound for weight reduction, uses a central processor instead of your Part D plan, and charges eligible beneficiaries a flat $50 monthly copay. [1]
That makes this less like a normal refill and more like a document-driven launch. If you wait until July to figure out which plan you have, what your starting BMI was, or whether your prescription belongs under the bridge versus regular Part D, you are setting yourself up for delays. For the broader timeline first, read our Medicare GLP-1 coverage overview. For the bigger coverage picture beyond Medicare, keep our insurance guide open too.
What actually starts on July 1, 2026
CMS announced BALANCE in December 2025 as the longer model that can begin in Medicaid as early as May 2026 and in Medicare Part D in January 2027. The Medicare piece that starts this summer is different: it is a separate short-term demonstration called the Medicare GLP-1 Bridge. [2] [3] [4]
That distinction matters because readers often hear “Medicare starts covering GLP-1s in 2026” and assume a full permanent Part D benefit change. That is not what CMS has published. The current structure is:
- July 1, 2026 to December 31, 2026: the Medicare GLP-1 Bridge
- January 1, 2027: BALANCE is expected to begin in participating Medicare Part D plans
- Longer term: access depends on whether your 2027 Part D plan participates in BALANCE [1] [2] [5]
So the practical question is not just “Will Medicare cover it?” The practical question is “Am I ready to qualify for the bridge on July 1, and do I understand what happens after December 31?”
Who should use this checklist
This checklist is for Medicare beneficiaries who think they may try to access Wegovy or Zepbound for weight reduction through the bridge starting July 1. CMS says beneficiaries must be enrolled in an eligible standalone Part D plan or an eligible Medicare Advantage plan with drug coverage in calendar year 2026 and must meet specific prior-authorization criteria. [1]
The checklist is also useful for caregivers and clinic staff because the bridge rules depend on details many people do not have handy:
- the exact Part D plan type
- the patient’s BMI at the time GLP-1 therapy started
- the diagnoses that fit the CMS bridge criteria
- whether the request belongs under the bridge or under regular Part D instead [1]
That last point is easy to miss. If the prescription is for a use that Medicare Part D already covers, such as Wegovy for cardiovascular risk reduction or Zepbound for obstructive sleep apnea, CMS says the request should still go through the beneficiary’s normal Part D plan, not the bridge. [1] [6] [7]
Step-by-step Medicare GLP-1 Bridge checklist
1. Confirm your 2026 drug coverage type
Before you worry about BMI or diagnosis rules, make sure you are actually enrolled in an eligible 2026 drug plan. CMS says the bridge is available to people enrolled in a standalone PDP or in an eligible MA-PD coordinated care plan. Some beneficiaries in special plan types are still eligible, while others are not unless they also have a standalone PDP. [1]
What to gather now:
- your 2026 Part D plan name
- your member ID card
- whether you are in a standalone PDP or Medicare Advantage with drug coverage
- whether you are in a special plan type that may need an extra eligibility check
If you do not know the plan type, solve that first. Everything else depends on it.
2. Figure out whether your request belongs under the bridge or regular Part D
This is the most common decision error. The bridge is for eligible GLP-1 use to reduce excess body weight and maintain weight reduction. But CMS separately says if a beneficiary is prescribed an eligible GLP-1 for a use already coverable under standard Part D, the provider should work through the beneficiary’s Part D plan instead of the bridge central processor. [1]
Two current examples:
- Wegovy can go through regular Part D when it is prescribed to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. [6]
- Zepbound can go through regular Part D when it is prescribed for moderate-to-severe obstructive sleep apnea in adults with obesity. [7]
If you are not sure which route applies, ask your prescriber’s office this exact question: “Is this request being submitted for bridge obesity coverage, or for a currently covered Part D indication?“
3. Pull your starting BMI, not just your current weight
CMS is unusually specific here. The bridge criteria rely on BMI at the time of initiation of GLP-1 therapy, not just the weight you have today. [1]
That means you should gather:
- the visit note or chart entry from when GLP-1 therapy started
- height and weight from that time
- your current weight
- any clinician documentation that shows when treatment began
If those older numbers are buried in portal messages, outside records, or paper charts, get them now. This is exactly the kind of detail that slows a July launch.
4. Match your diagnosis to the bridge criteria
CMS says the provider’s prior authorization needs to attest that the beneficiary is at least 18, is using the drug together with current and ongoing lifestyle modification, and met one of the bridge pathways when GLP-1 therapy began: [1]
- BMI 35 or higher
- BMI 30 or higher plus heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or above
- BMI 27 or higher plus prediabetes, previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease
So your preparation list should include any records that clearly show those conditions, such as cardiology notes, kidney-disease staging, blood-pressure treatment history, or prior stroke documentation. If your chart uses vague language and never clearly states the qualifying diagnosis, ask the office to clean that up before July.
5. Gather proof of ongoing lifestyle treatment
CMS says bridge coverage requires the medication to be used in combination with current and ongoing lifestyle modification including structured nutrition and physical activity consistent with the FDA-approved label. [1] [2]
That does not necessarily mean you need a commercial diet subscription. It does mean the prescriber should be able to document that the medication is part of an active weight-management plan.
Good items to gather:
- nutrition counseling notes
- clinician notes mentioning reduced-calorie diet, meal planning, or structured nutrition support
- physical-activity counseling or exercise-plan documentation
- follow-up notes showing you are still actively doing the lifestyle part of treatment
The goal is not to create theater. The goal is to make the prior authorization file coherent.
6. Prepare for the cost-sharing difference
The bridge’s $50 monthly copay sounds simple, but it works differently from normal Part D spending. CMS says the bridge operates outside the Part D benefit, so the $50 you pay does not count toward your deductible, true out-of-pocket spending, or the annual out-of-pocket cap. KFF also notes that low-income cost-sharing subsidies do not apply to bridge fills because they are outside the Part D benefit flow. [1] [5]
The practical implication: if you use the bridge, do not assume those fills are helping you move through the normal Part D phases. Budget for the bridge as its own short-term spending bucket.
7. Ask the clinic who will actually submit the bridge paperwork
CMS says bridge requests will go to a single central processor, not to the patient’s Part D plan. That is a different workflow than many offices use every day. [1]
Before July 1, ask:
- who in the office handles bridge prior authorizations
- whether they already know the bridge workflow
- whether they have the records needed to prove your start BMI and qualifying conditions
- how they want you to send outside records if your history is spread across multiple systems
If the office sounds surprised that the bridge does not go through the plan, that is a signal to slow down and clarify the process before launch day.
What to do this week
If you want a short action plan, use this one:
- Find your 2026 Part D card and confirm your plan type.
- Send a portal message asking for your starting BMI, start date, and qualifying diagnoses to be pulled into one note.
- Ask whether your request belongs under the bridge or under regular Part D because of cardiovascular disease or sleep apnea.
- Gather proof that your treatment has included ongoing nutrition and physical-activity work.
- Make a one-page list of your current medications, prescribers, and the clinics that hold your older records.
That list sounds basic, but it prevents the most avoidable launch problem: scattered records that leave the office guessing when the prior authorization window opens.
Questions to ask your clinician, pharmacy, or plan
Use these at the next call or visit:
| Ask this | Why it matters |
|---|---|
| Does my request belong under the Medicare GLP-1 Bridge or standard Part D coverage? | The paperwork route changes depending on the indication. |
| Do you have my BMI from when GLP-1 therapy started, not just my current weight? | CMS ties bridge eligibility to the BMI at treatment initiation. |
| Which diagnosis in my chart is the one that actually makes me eligible? | ”Obesity” alone is not always enough at lower BMI thresholds. |
| Do you need records from another health system before July 1? | Outside cardiology, nephrology, or hospital records may prove eligibility. |
| If I start on the bridge in 2026, what is the plan for 2027 open enrollment? | Continued access after December 31 depends on BALANCE participation. |
What is still uncertain
The bridge rules are clearer than they were in December, but some important details are still unsettled.
The biggest unknown is 2027 continuity. CMS says beneficiaries who use the bridge and want continued weight-loss coverage in 2027 will need a Part D plan that opts into BALANCE. Since BALANCE participation is voluntary for Part D sponsors, nobody should assume every plan will be in the program. [2] [5]
There is also normal rollout uncertainty around education, clinic workflows, and transition instructions. CMS has said it will provide additional implementation information and outreach, but the operational burden in the first weeks will still fall on clinics, pharmacies, and beneficiaries who have the cleanest records ready to go. [1] [4]
The honest bottom line is this: the best preparation is not speculative shopping. It is record cleanup. By July 1, the people in the strongest position will be the ones who already know their plan type, their start BMI, their qualifying diagnosis, and which coverage route their prescriber intends to use.
